Trial Profile
A Phase 3, Multicenter, Randomized, Open-label, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Chlorambucil
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ORIGIN
- Sponsors Celgene Corporation
- 18 Dec 2021 This trial has been completed in Italy, European Clinical Trials Database record. (9 May 2018)
- 24 Sep 2019 This trial has been completed in Portugal
- 28 Feb 2019 This study has been completed in UK - MHRA.